SonoMind, a medical device company based in Paris, France, has successfully raised $3,000,000 in a recent funding round. This new capital infusion is set to accelerate the development and commercialization of its innovative non-invasive brain stimulation technology for neurological and psychiatric conditions.
The company specializes in utilizing low-intensity focused ultrasound to treat drug-resistant depression and other complex conditions. SonoMind's portable device is notable as the first to deliver precision transcranial ultrasound stimulation capable of penetrating deep brain structures in an accurate, targeted, and non-invasive manner. Each patient benefits from a custom-designed acoustic lens, which ensures ultrasound waves effectively pass through the skull and compensate for any distortion upon entering the brain.
This significant investment underscores the potential of SonoMind's technology to address critical unmet needs in neurological and psychiatric care. The funding round will enable SonoMind, led by CEO Jeremy Bercoff and supported by a ten-person team, to expand its operational capabilities and advance its research efforts. The company leverages 25 years of foundational research undertaken by Profs. Mickael Tanter and Jean-François Aubry at the Institut Physique pour la Médecine.
SonoMind plans to use the funds for strategic growth initiatives, including further research and development, scaling up its clinical validation processes, and preparing for market entry. This capital is crucial for advancing its mission to provide accessible, targeted treatments for complex brain disorders.
The company looks forward to leveraging this investment to solidify its position as a leader in non-invasive neuromodulation, aiming to bring its device to patients worldwide and drive improvements in mental health outcomes.
